With the addition of ARSIs like the -lutamides, castrate-resistance is postponed indefinitely for some patients; it just depends on the idiosyncrasies of each person's cancer.

And — not a doctor — but I think that the oncology community's thinking is changing from "ADT causes castrate-resistance" to "ADT unmasks castrate-resistance".

If a tiny percentage of your cancer is already castrate-resistant, you won't notice it if you let the castrate-sensitive cancer spread unchecked, just like you won't notice dry rot if your house is on fire. It's only when you put out the fire that the dry rot becomes a problem.